We are live on !
Find out more
Commodore Capital Portfolio holdings
AUM
$1.68B
Turnover
31.71%
1-Year Est. Return
375.52%
This Fund
S&P 500
This Quarter Est. Return
-0.98%
1 Year Est. Return
+375.52%
3 Year Est. Return
+2,120.72%
5 Year Est. Return
+8,694.03%
10 Year Est. Return
–
AUM
$473M
AUM Growth
+$25.3M
(+5.6%)
Cap. Flow
+$53.8M
Cap. Flow % of AUM
Cap. Flow %
11.37%
Top 10 Holdings %
Top 10 Hldgs %
75.64%
Holding
30
New
3
Increased
11
Reduced
4
Closed
6
Avg Time Held
0.9
years
Top 10 Avg Time Held
0.8
years
Top 20 Avg Time Held
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merus
MRUS
|
+$16.7M |
| 2 |
Kura Oncology
KURA
|
+$15.1M |
| 3 |
Xenon Pharmaceuticals
XENE
|
+$11.9M |
| 4 |
Arrowhead Research
ARWR
|
+$11.8M |
| 5 |
Cogent Biosciences
COGT
|
+$9.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
C4 Therapeutics
CCCC
|
+$11.7M |
| 2 |
Karyopharm Therapeutics
KPTI
|
+$9.9M |
| 3 |
BLU
BELLUS Health Inc.
BLU
|
+$9.47M |
| 4 |
Protagonist Therapeutics
PTGX
|
+$7.86M |
| 5 |
GNCA
Genocea Biosciences, Inc.
GNCA
|
+$3.85M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.48% |
| 2 | Financials | 0.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
DELISTED
Merus
MRUS
| $59.2M | 12.52% |
2,615,762
+799,341
| +44% | +$16.7M |
2021 Q3
3 quarters
|
|
|
2
Xenon Pharmaceuticals
XENE
$3.42B
| $48.5M | 10.26% |
1,594,932
+392,319
| +33% | +$11.9M |
2020 Q4
6 quarters
|
|
|
3
Cogent Biosciences
COGT
$5.42B
| $44.6M | 9.43% |
4,944,708
+1,443,940
| +41% | +$9.9M |
2020 Q4
6 quarters
|
|
|
BLU
4
DELISTED
BELLUS Health Inc.
BLU
| $41.4M | 8.75% |
4,479,784
-1,157,846
| -21% | -$9.47M |
2021 Q4
2 quarters
|
|
5
Cytokinetics
CYTK
$8.51B
| $35.1M | 7.42% |
893,646
+38,994
| +5% | +$1.57M |
2021 Q2
4 quarters
|
|
6
Aclaris Therapeutics
ACRS
$552M
| $33.7M | 7.12% |
2,410,622
+95,974
| +4% | +$1.34M |
2020 Q4
6 quarters
|
|
|
7
Kura Oncology
KURA
$855M
| $33.5M | 7.08% |
1,826,491
+1,049,977
| +135% | +$15.1M |
2022 Q1
1 quarter
|
|
|
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $23.2M | 4.9% |
2,409,961
+195,000
| +9% | +$2.45M |
2020 Q4
6 quarters
|
|
|
TCDA
9
DELISTED
Tricida, Inc. Common Stock
TCDA
| $19.6M | 4.15% |
2,028,453
+283,883
| +16% | +$2.7M |
2021 Q4
2 quarters
|
|
10
Viridian Therapeutics
VRDN
$2.53B
| $19M | 4.01% |
1,638,609
+687,270
| +72% | +$9.24M |
2021 Q1
5 quarters
|
|
11
DELISTED
Cymabay Therapeutics
CBAY
| $16.9M | 3.58% |
5,738,500
| – | – |
2020 Q4
6 quarters
|
|
|
STSA
12
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $15.4M | 3.25% |
3,711,286
| – | – |
2021 Q1
5 quarters
|
|
13
Celldex Therapeutics
CLDX
$2.3B
| $14.5M | 3.07% |
538,812
+297,613
| +123% | +$8.64M |
2022 Q1
1 quarter
|
|
14
DELISTED
Day One Biopharmaceuticals
DAWN
| $13.2M | 2.8% |
+739,661
| New | +$7.64M |
2022 Q2
0 quarters
|
|
15
VistaGen Therapeutics
VTGN
$7.97M
| $11.5M | 2.43% |
434,969
+98,395
| +29% | +$3.47M |
2020 Q4
6 quarters
|
|
|
16
Arrowhead Research
ARWR
$8.2B
| $11M | 2.33% |
+312,533
| New | +$11.8M |
2022 Q2
0 quarters
|
|
|
17
Karyopharm Therapeutics
KPTI
$11.7M
| $8.73M | 1.85% |
129,041
-108,362
| -46% | -$9.9M |
2022 Q1
1 quarter
|
|
18
Celcuity
CELC
$3.19B
| $8.38M | 1.77% |
920,464
| – | – |
2021 Q2
4 quarters
|
|
19
Rezolute
RZLT
$372M
| $3.91M | 0.83% |
+1,210,000
| New | +$4.02M |
2022 Q2
0 quarters
|
|
20
Immunic
IMUX
$101M
| $3.1M | 0.66% |
89,301
| – | – |
2022 Q1
1 quarter
|
|
21
DELISTED
KalVista Pharmaceuticals
KALV
| $3.08M | 0.65% |
312,553
| – | – |
2021 Q1
5 quarters
|
|
|
BLSA
22
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $2.48M | 0.52% |
250,000
| – | – |
2020 Q4
6 quarters
|
|
23
Tenaya Therapeutics
TNYA
$87.2M
| $2.01M | 0.43% |
357,699
-156,231
| -30% | -$1.26M |
2021 Q3
3 quarters
|
|
24
Inventiva
IVA
$876M
| $995K | 0.21% |
175,500
-87,158
| -33% | -$792K |
2020 Q4
6 quarters
|
|
|
25
C4 Therapeutics
CCCC
$376M
| – | – |
-481,094
| Closed | -$11.7M | – |
|
Similar funds
SH
TP
IAIM
Commodore Capital's Q2 2022 Portfolio in Review
As of Q2 2022, Commodore Capital held 30 positions worth $473M, up 5.6% from $448M the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Commodore Capital deployed $53.8M of net new capital in Q2 2022, opening 3 new positions and adding to 11 existing holdings. Its largest new stake was Arrowhead Research: 312,533 shares worth $11M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Karyopharm Therapeutics, an estimated $9.9M trimmed.
- Commodore Capital's largest Q2 2022 buy was Arrowhead Research: 312,533 shares worth $11M.
- Commodore Capital added most to Merus in Q2 2022, an estimated $16.7M increase.
- Commodore Capital's biggest Q2 2022 reduction was Karyopharm Therapeutics, cutting an estimated $9.9M.
- Commodore Capital fully exited C4 Therapeutics in Q2 2022, selling an estimated $11.7M.
- Commodore Capital's ten largest holdings make up 76% of its $473M portfolio in Q2 2022.
- Commodore Capital opened 3 new positions and closed 6 in Q2 2022.
- Commodore Capital's portfolio value rose 5.6% quarter-over-quarter to $473M.
Based on Commodore Capital's 13F filing for Q2 2022, filed 15 Aug 2022.